Contouring the face of Brazilian consumption with vanity

A consumer base more likely to invest in beauty products, weight loss pens, and digital platforms has pumped the growth of Brazil’s pharmaceutical sector and lifted local stocks this year.

Brazil’s large population and its worldwide recognition for beauty make it a haven for players in the cosmetics industry. The recent popularity of slimming pens, initially used to treat diabetes, has further boosted the country’s pharmaceutical and retail markets, opening this billion-dollar sector to new investment possibilities and creating more opportunities for short-term returns.

This comes as no surprise. More than 2 million procedures are done in Brazil each year, one of the highest in the world according to the 2024 ISAPS report. The country ranks second in terms of non-surgical procedures, behind only the US. Further, the Brazilian Society of Plastic Surgery reports that plastic surgeries represent a market of BRL 48 billion (USD 9.31 billion) annually, making it the fourth highest spender on cosmetic procedures globally after the US, China, and Japan. These figures highlight the scale of Brazilian spending on the beauty market and the investment potential that comes with it.

Slimming pens fever

The market for beauty-related products has also grown, driven by the popularity of weight loss injectables. While the original intent is to help diabetes patients control their blood sugar at home, the slimming side effect of these injectable pens has become the more prominent selling point as it helps people lose weight faster than any medication sold in pharmacies. As a result, these pens have strengthened Brazil’s retail pharmaceutical segment and transformed it into one of the most resilient sectors on the domestic stock exchange.

Although the pens remain the main source of atypical growth, the sector’s momentum has also been driven by the diversification of the product mix. Categories such as dermo-cosmetics are also gaining relevance. As Graph 1 shows, the sector has grown at a steady pace since 2018, far exceeding the revenue performance of the entire retail sector in the last eight years except in 2021. By 2025, the sector expanded by 9.5 per cent while other retail segments only grew by 4 per cent.

Weight loss drives gains

The high demand for this class medication has boosted sales during the past few months, and the growth is expected to continue driving the pharmaceutical sector upward throughout 2026. This outlook is also sustained by a positive macroeconomic environment, with the unemployment rate touching record lows and rising average household incomes.

Additionally, longer life expectancy could come into play to sustain the growth of the sector. New research shows that Brazil has approximately 59 million people aged 50 or older called the “silver generation”, equivalent to 27 per cent of the population and representing 35 per cent of health-related spending on products and services in 2024. By 2044, the survey forecasts that this age group will spend even more on healthcare, such as on medicines, medical examinations, and health insurance plans, to account for 50 per cent of aggregate household healthcare spending.

Further, digital channels are consolidating their relevance in Brazilian retail, especially in categories such as beauty and personal care. This can be another driver to sustain the rhythm of growth of pharmaceuticals.

Lifting Brazilian stocks

Compared to the pharmaceutical retail sector in other countries, Brazil’s is one of the least concentrated despite the strong demand for beauty care products. Three of its main drugstore chains constitute less than 30 per cent of the market, while the five largest pharmacies in the country represent only a third of total market share. In comparison, the US’ five biggest pharmaceutical store brands control 81 per cent of their market. So, there is much room for global investors to diversify their assets across more Brazilian pharmaceutical stocks and mitigate risks while still able to realise gains from this fast-growing segment.  

To illustrate further, Graph 2 compares the two biggest listed pharmaceutical chains against the Bovespa index wherein these stocks delivered higher returns over the past 12 months, particularly for most of 2025. Returns have partially slipped this year to match the performance of the main index as of end-June, making share prices more attractive to new entrants.

Given the trajectory of pharmaceutical demand, large drugstore chains such as Panvel and Raia Drogasil are investing in the expansion of their store network and digital service platforms, which may drive higher revenues in the coming months. Some companies are also investing in private label products which could raise their margin and, consequently, their profits. Others are introducing the self-service model and allowing customers to pay for household utility bills, banking on the high foot traffic in stores. More importantly, the sector is investing in consultation rooms within pharmacies, where customers can have face-to-face consultations with a pharmacist and access quick medical services such as measuring blood pressure and glucose monitoring. There are also some chains investing in connecting customers to doctors via teleconsultation.

The outlook for Brazil’s pharma sector profits looks solid as companies build on the combination of strong demand for slimming pens and wider availability of medicines, additional investments in drugstore innovation and productivity, as well as the potential for market share gains. The year 2026 is shaping up into an environment of stronger growth for Brazil, with the pharmaceutical retail sector remaining among the highlights of the Bovespa index. It is no surprise that pharmaceuticals will be the market’s head-turner in the medium term with the prospect of potentially handsome returns.

This original article has been produced in-house for Lundgreen’s Investor Insights by on-the-ground contributors of the region. The insight provided is informed with accurate data from reliable sources and has gone through various processes to ensure that the information upholds the integrity and values of the Lundgreen’s brand.